Ipamorelin

Ipamorelin is a synthetic peptide five amino acids long, built at Novo Nordisk in the 1990s as a copy of ghrelin, the stomach hormone that tells the brain you are hungry and, separately, nudges the pituitary gland to let go of growth hormone. It is not growth hormone itself. It is a message asking your own pituitary to release its own growth hormone, which means it only does anything if that gland still works. What made it notable in the lab was selectivity: the earlier growth hormone-releasing peptides it was designed to improve on, GHRP-6 and GHRP-2, also drove up adrenocorticotropic hormone (ACTH, the signal that tells the adrenal glands to make cortisol) and cortisol itself, while ipamorelin did not raise either above the level seen with growth hormone-releasing hormone alone. Despite thirty years of that reputation it has never been approved as a medicine anywhere, and the two human trials that exist both gave it by intravenous drip — one to healthy volunteers for a few hours of blood sampling, the other to people recovering from bowel surgery.

• Raising your own growth hormone rather than injecting growth hormone itself
• Body composition goals over months: less fat, more lean mass. This is a clinic and online use, not one any trial has measured
• Sleep quality, on the reasoning that the biggest natural growth hormone pulse happens during early deep sleep
• Recovery from hard training and soft-tissue wear
• Recovery of gut motility after abdominal surgery, which is what it was actually developed and tested for, and where it failed its trial

Picture your pituitary gland as a bucket with a spring-loaded lid that flips open a few times a day and tips some growth hormone out. Ghrelin is the hand that taps the lid open, and ipamorelin is a copy of that hand. Older copies of the hand were clumsy and knocked the neighbouring cortisol bucket over at the same time; this one was designed to reach only the growth hormone lid. But it is still just a tap on a lid, so nothing new goes into the bucket, and the tap lasts about an hour before the lid springs shut again.

1. First doseIn healthy men given ipamorelin intravenously, growth hormone rose as a single episode peaking around 40 minutes after the dose, then fell back toward negligible levels. The peptide itself has a terminal half-life of roughly two hours (Gobburu et al., 1999).
2. Week 1-2Nothing measurable has been published for this window. Users commonly describe deeper sleep and more appetite in the first nights, which fits a ghrelin mimetic, but appetite and sleep were not endpoints in either human trial.
3. Week 4-8Any change in body composition would show up here at the earliest. No human trial has measured fat mass, lean mass or insulin-like growth factor 1 (IGF-1) on ipamorelin, so there is no timeline to quote. In rats dosed for 15 days, bone growth and body weight rose but IGF-1 did not move (Johansen et al., 1999).
4. Month 3+The cheatsheet cycle runs 12 to 16 weeks. The longest human exposure ever published is seven days. What happens over three months of nightly subcutaneous dosing is unknown rather than reassuring.
5. Post-cycleClearance is fast, so the peptide is gone within a day of the last dose. Whether the pituitary response blunts with continuous use has only been looked at in rats, where responsiveness to a challenge dose was marginally reduced after 15 days (Johansen et al., 1999).

• In the 117-patient surgical trial, hypokalemia (low blood potassium) occurred in 12.5 percent on ipamorelin versus 3.4 percent on placebo, and insomnia in 10.7 percent versus 5.2 percent.
• Hyperglycemia at discharge was recorded in 14.3 percent on ipamorelin versus 8.6 percent on placebo in that same trial. Raised blood sugar is the expected consequence of pushing growth hormone up.
• Nausea, vomiting and abdominal distension were the most common events in that trial overall, though numerically lower on ipamorelin than placebo, and most were attributed to the surgery.
• Three participants stopped the drug for nausea, high blood pressure or low blood pressure.
• Increased hunger, which follows directly from activating the ghrelin receptor, is widely reported by users and is consistent with the mechanism.
• Water retention, puffy hands or feet, joint aching and carpal tunnel symptoms are recognised consequences of sustained growth hormone and IGF-1 elevation. They are not specific findings for ipamorelin, because no trial has run long enough to look.
• Two deaths occurred among ipamorelin-treated participants in the surgical trial, both after bowel resection for colon cancer complicated by anastomotic leak. Causality was not established, but the FDA cites these events in its published record on the substance.

• You are pregnant, trying to conceive, or breastfeeding. There is no human pregnancy data, and in mice both activating and blocking the ghrelin receptor harmed fertilisation, implantation and embryo development.
• You have an active cancer or a personal history of one. Growth hormone and IGF-1 are growth signals, and increased risk of neoplasm is a labelled warning on every approved growth hormone product.
• You have diabetes, prediabetes or poor glucose control. Hyperglycemia was more frequent on ipamorelin than placebo in the only controlled trial that measured it.
• You are recovering from bowel surgery or have a bowel anastomosis, given what the surgical trial recorded.
• You have a known pituitary lesion, acromegaly, or complete growth hormone deficiency, since with no working somatotroph cells there is nothing for it to act on.
• You are a child or adolescent with open growth plates, unless an endocrinologist is directing it.
• You are an athlete subject to drug testing. Ipamorelin is named on the World Anti-Doping Agency Prohibited List.
• You are not under a physician who can order fasting glucose, HbA1c and IGF-1 before and during use.

• Treating it as growth hormone. It is a request to a gland, and if your own pituitary output is genuinely low for a medical reason, this will not substitute for the approved treatment.
• Dosing right after a meal. Food, and carbohydrate in particular, blunts the growth hormone pulse, which is why the cheatsheet timing is before sleep on an empty stomach.
• Reconstituting badly: use bacteriostatic water, aim the stream at the glass wall rather than straight into the powder, and swirl instead of shaking. The FDA record on this peptide names aggregation as a specific concern, and aggregation is what rough handling encourages.
• Storing the mixed vial in the fridge door, where the temperature cycles every time it opens, or leaving it at room temperature for days.
• Assuming the selectivity argument covers everything. Not raising cortisol is a real and well-documented property; it says nothing about glucose, potassium or long-term exposure, which is where the actual trial signals were.
• Running it back to back without breaks, or stacking it with a second ghrelin mimetic or an oral secretagogue on the theory that more receptor activation is better. No study has characterised the metabolic cost of that.